|
|
Home → Volume 1/ Issue 5 → Newer Treatments → Anti-Tumor Necrosis Factor Therapy
159.
TREATMENT WITH INFLIXIMAB FOR INDICATIONS OTHER THAN POLY
ARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS (POLY JRA):
THE ROLE OF THE RHEUMATOLOGY CLINIC NURSE
SJ Parker, RM Laxer, R Schneider, BM Feldman, ED Silverman
160.
EXPANDED REVIEW OF INFLIXIMAB THERAPY FOR STEROID-DEPENDENT
EARLY ONSET SARCOID ARTHRITIS AND BLAU SYNDROME: 5 PEDIATRIC
CASES
AC Brescia, G McIlvain-Simpson, CD Rose
161. SEVERE AUTOIMMUNE DISEASE IN SIBLINGS OF A SOMALIAN FAMILY AND
RESPONSE TO TREATMENT WITH INFLIXIMAB
NMR Wilkinson, PA Livermore, P Woo
141. INFLIXIMAB IN REFRACTORY BEHCET'S DISEASE IN CHILDREN
Y Kimura
50. ANTI-TUMOR NECROSIS FACTOR THERAPY LEADS TO IMPROVEMENT OF
ENTHESITIS AND SYNOVITIS IN CHILDREN WITH
ENTHESITIS-RELATED
ARTHRITIS
SML Tse, A Doria, P Babyn, C. Boros, S Parker, BM Feldman, RM
Laxer
51 THERAPEUTIC
USE OF ETANERCEPT IN POLYARTICULAR COURSE JUVENILE
RHEUMATOID ARTHRITIS OVER A
3-4 YEAR PERIOD
TL Moore, U Daud, DA Kietz, PH Pepmueller
52. RESPONSE TO
ETANERCEPT IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
Y Kimura,
P Pinho, G Higgins, D Hummell, I Szer, M Henrickson, D Goldsmith,
C Wallace, D Rothman,
J Hollister, S Li.
53.
CLINICAL
RESPONSES TO ETANERCEPT IN SYSTEMIC ARTHRITIS MEASURE
BY "CORE SET" OUTCOME VARIABLES
KM Bailey, CJ Ryder, TR Southwood
56. NIACIN-LIKE
EFFECT ASSOCIATED WITH INFLIXIMAB THERAPY IN SYSTEMIC
JRA
G McIlvain-Simpson, ML Becker, CD Rose
57.
THE
BENEFICIAL EFFECT OF INFLIXIMAB IN AMYLOIDOSIS SECONDARY TO
JIA: A CASE WITH A 20 MONTH FOLLOW-UP
H Ozdogan,
F Gogus, S Masatlioglu, D Cevirgen
58.
DISSEMINATED HERPES
SIMPLEX INFECTION PRECIPITATING MACROPHAGE
ACTIVATION SYNDROME IN A CHILD WITH SYSTEMIC JUVENILE
IDIOPATHIC
ARTHRITIS UNDERGOING THERAPY WITH INFLIXIMAB
JM Skripak, GL Rodgers,
C Martucci, DP Goldsmith
59. TREATMENT OF
JUVENILE ONSET IDIOPATHIC ARTHRITIS WITH INFLIXIMAB
H Ozdogan, F Gogus, S Masatlioglu, D Cevirgen
